Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Conditions
- ALL, ChildhoodALLAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 15
- Registration Number
- NCT03571321
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Leukemia, AcuteLeukemia, T CellLeukemia, Lymphoblastic
- Interventions
- Procedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
- Interventions
- Biological: BlinatumomabBiological: FilgrastimOther: Laboratory Biomarker AnalysisBiological: PegfilgrastimBiological: Rituximab
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03518112
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia in RemissionB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Biological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisBiological: OfatumumabBiological: Rituximab
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03488225
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪Universitatsklinikum Munster, Münster, Germany
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 9
- Registration Number
- NCT03370601
- Locations
- 🇫🇷
CHRU, Hôpital Claude Huriez, Lille, France
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- Conditions
- Childhood CancerAcute Lymphoblastic LeukemiaDown Syndrome
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- National Hospital Organization Nagoya Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT03286634
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 310
- Registration Number
- NCT03150693
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Acute Lymphoblastic LeukemiaAcute Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 560
- Registration Number
- NCT03020030
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.